Omega-3-acid ethyl esters
Brand names: Omacor
Omega-3-acid ethyl esters are a lipid-regulating preparation of eicosapentaenoic and docosahexaenoic acid ethyl esters, used as an adjunct in severe hypertriglyceridaemia.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
They reduce hepatic synthesis of triglycerides and very-low-density lipoprotein, lowering serum triglyceride concentrations; the precise mechanisms include effects on fatty acid metabolism and substrate availability.
Prescribing in practice
- They may modestly prolong bleeding time and should be used with caution in patients on anticoagulants or antiplatelet agents and around surgery.
- Routine post-myocardial-infarction use is no longer generally recommended, as later evidence did not confirm a consistent cardiovascular benefit for this preparation; its main role is in hypertriglyceridaemia.
- Caution is advised in those with fish or seafood allergy and in hepatic impairment; consult the SPC.
Monitoring
Monitor the fasting lipid profile, and liver function where there is hepatic impairment.
Counselling the patient
- Advise taking the capsules with food to reduce indigestion and fishy aftertaste.
- Tell the patient to mention this medicine before any surgery or if they take blood-thinning drugs.
Evidence & guidelines
Omega-3-acid ethyl esters lower triglycerides but later trials did not confirm broad cardiovascular benefit for this preparation; refer to current prescribing references.
Reference: NICE CG181; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines